Alteo

Alteogen is a leading South Korean biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates (ADCs), and biosimilars. The company is best known for its Hybrozyme platform technology, which enables the large-scale production of a human recombinant hyaluronidase (ALT-B4) used to convert intravenous (IV) drugs into subcutaneous (SC) formulations. This technology has been the subject of multi-billion dollar licensing deals with major pharmaceutical companies, including Merck and Sandoz. Beyond its platform, Alteogen maintains a robust internal pipeline focused on oncology and ophthalmology, including a HER2-targeted ADC and an Eylea biosimilar.